Brook Byers

He has been closely involved with more than fifty new technology based ventures, over half of which have already become public companies.

KPCB has invested in and helped build over 110 Life Sciences companies which have already developed hundreds of products to treat major underserved medical needs for millions of patients.

He is often featured on the Forbes Midas list and is currently on the board of directors of ten companies; CardioDX, Crescendo Bioscience, Inc., Genomic Health Incorporated, Five Prime Therapeutics, OptiMedica, HX Diagnostics, Pacific Biosciences, Inc., Tethys, Veracyte, Inc., and XDx, Inc.[4] Previously, he served on the board of directors of Idec Pharmaceuticals (chairman), Athena Neurosciences (chairman), Signal Pharmaceuticals, Arris Pharmaceuticals, Pharmacopeia, Ligand Pharmaceuticals (chairman), Hybritech (chairman), Genprobe, Nanogen, and others.

He is currently a board member of the University of California at San Francisco Medical Foundation, the California Healthcare Institute, the NewSchools Venture Fund, Stanford's Bio-X Advisory Council, the Stanford Eye Council and TechNet.

He was formerly a director of the Entrepreneurs Foundation, the California Healthcare Institute, the Asian Art Museum of San Francisco, the Stanford University Graduate School of Business Advisory Council, UCSF's That Man May See Vision Research Foundation (chairman), and the Georgia Tech Advisory Board, and was a founder of TechNet.